World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
71
Citations
35302
World Ranking
2265
National Ranking
1096

Medicine

D-Index
72
Citations
35555
World Ranking
19747
National Ranking
9835

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Naomi F. Rothfield was affiliated with the University of Connecticut in the United States during their academic career. Their contributions to medical and scientific research were recognized within professional circles, as reflected by their membership in the Association of American Physicians.

While detailed records of their research publications, coauthors, and frequent publication venues are not available, this scientist's career was distinguished by involvement in advancing knowledge within their field.

There is no information on specific research papers, book publications, or detailed topics of study related to Naomi F. Rothfield. However, their association with a major research university suggests active participation in academic and clinical research activities.

Their status as deceased indicates that their work belongs to a previous era of scientific investigation, but the acknowledgment by a recognized medical association confirms a level of professional engagement and recognition during their lifetime.

Best Publications

  • The 1982 revised criteria for the classification of systemic lupus erythematosus

    Eng M. Tan;Alan S. Cohen;James F. Fries;Alfonse T. Masi

  • Cyclophosphamide versus placebo in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Jonathan Goldin

  • Range of antinuclear antibodies in "healthy" individuals

    E. M. Tan;T. E. W. Feltkamp;J. S. Smolen;B. Butcher

  • Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma.

    William C. Earnshaw;Naomi Rothfield

  • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

    Donald P. Tashkin;Robert Elashoff;Philip J. Clements;Michael D. Roth

  • Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen

    William C. Earnshaw;Kevin E Sullivan;Paula S. Machlin;Carol A. Cooke

  • CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate

    Hisato Saitoh;John Tomkiel;Carol A. Cooke;Harry Ratrie

  • High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients.

    JH Shero;B Bordwell;NF Rothfield;WC Earnshaw

  • Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

    Peter A. Merkel;Peter A. Merkel;Karen Herlyn;Richard W. Martin;Jennifer J. Anderson

  • Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

    James R. Seibold;Joseph H. Korn;Robert Simms;Phillip J. Clements

  • The Clinical Course of the Proliferative and Membranous Forms of Lupus Nephritis

    David S. Baldwin;Jerome Lowenstein;Naomi F. Rothfield;Gloria Gallo

  • cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment

    Peter D'Arpa;Paula S. Machlin;Harry Ratrie;Naomi F. Rothfield

  • Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.

    E S Weiner;W C Earnshaw;J L Senécal;B Bordwell

  • Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.

    W Earnshaw;B Bordwell;C Marino;N Rothfield

  • Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus.

    Matthew D. Linnik;Jay Z. Hu;Kenneth R. Heilbrunn;Vibeke Strand

  • Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study

    Fredrick M. Wigley;Joseph H. Korn;M. E. Csuka;Thomas A. Medsger

  • Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.

    Megan E. B. Clowse;Daniel J. Wallace;Richard A. Furie;Michelle A. Petri

  • Lupus erythematosus: systemic and cutaneous manifestations

    Naomi Rothfield;Richard D. Sontheimer;Megan Bernstein

  • Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

    Mario H. Cardiel;James A. Tumlin;Richard A. Furie;Daniel J. Wallace

  • A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity.

    Eng M. Tan;Josef S. Smolen;J. S. McDougal;Brian T. Butcher

  • Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study.

    E S Weiner;S Hildebrandt;J L Senécal;L Daniels

  • Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus: Results of a multicenter randomized, double-blind, placebo-controlled trial

    Michelle A. Petri;Philip J. Mease;Joan T. Merrill;Robert G. Lahita

  • Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a Systemic Sclerosis Clinical Trial

    Dinesh Khanna;Daniel E. Furst;Philip J. Clements;Grace S. Park

Frequent Co-Authors

William C. Earnshaw
William C. Earnshaw University of Edinburgh
Maureen D. Mayes
Maureen D. Mayes The University of Texas at Austin
Virginia D. Steen
Virginia D. Steen Georgetown University
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Larry W. Moreland
Larry W. Moreland University of Colorado Anschutz Medical Campus
Peter A. Merkel
Peter A. Merkel University of Pennsylvania
Philip J. Clements
Philip J. Clements University of California, Los Angeles
Fredrick M. Wigley
Fredrick M. Wigley Johns Hopkins University
John Varga
John Varga University of Michigan–Ann Arbor
Thomas A. Medsger
Thomas A. Medsger University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, exploring related online degrees can open up diverse career opportunities in healthcare and research. Nursing roles, especially nurse practitioner programs, offer accessible pathways for professionals looking to specialize. Many students seek out the easiest NP programs to get into as a way to start their advanced clinical training with fewer admissions barriers.

Specializations such as psychiatric-mental health nurse practitioner (PMHNP) programs are valuable for those focused on mental health immunology intersections. The best PMHNP programs offer robust clinical placement rates, ensuring hands-on experience which is crucial for career advancement.

Cost is also a major consideration. Many learners turn to the cheapest online PMHNP certificate programs to gain credentials without incurring significant debt. These affordable options provide quality education while easing financial burdens.

Professionals with advanced degrees like a Doctor of Nursing Practice (DNP) often secure higher salaries. Understanding the highest paid DNP specialties can help guide those in immunology or related fields toward the most lucrative roles. Combining immunology knowledge with advanced nursing credentials can lead to impactful and well-compensated career paths.

Best Scientists Citing Naomi F. Rothfield

Recently Published Articles